Genome-wide mutation analyses and high-throughput deep sequencing have identified that 70% of grade II-III gliomas and secondary glioblastomas, as well as 10% of acute myeloid leukemia (AML), have mutations in IDH1 or IDH2 [11,12,13]. This evidence concerns the gene IDH2 and acute myeloid leukemia.